McKesson Buyback Strategy Boosts EPS Growth Amid Slower Income

Key Facts

As major corporations seek to bolster shareholder value amid market volatility, McKesson is actively pursuing a share buyback strategy that has led to significant EPS growth. According to reports, this strategy is successfully driving per-share value higher despite a backdrop of slower net income growth. The company currently delivers a 4.8% total shareholder yield, underpinned by robust cash flows and a solid balance sheet that facilitates this aggressive capital return program.

These moves come at a time when the pharmaceutical distribution sector is prioritizing operational efficiency, with peers such as Cencora and Cardinal Health showing similar capital reallocation trends. Compared to previous quarters, McKesson has maintained a negative cash conversion cycle, a key operational advantage that allows it to fund buybacks without straining liquidity. Per market data, the persistence of this momentum enhances the stock's appeal to investors seeking stable returns within the healthcare sector.

Regarding market performance, MCK stock closed at $784.23 (close July 06, 2026), with the day's trading range between a low of $776 and a high of $789.1. Investors are now watching the sustainability of these cash flows in the absence of immediate major economic catalysts in the financial calendar for this sector, focusing on the company's ability to balance buybacks against potential headwinds in drug pricing.